Mechanisms of hemolysis-associated platelet activation

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 12, 2013, Pages 2148-2154

  Helms, C C ^a   Marvel, M ^b   Zhao, W ^c   Stahle, M ^c   Vest, R ^b   Kato, G J ^d,e   Lee, J S ^e,f   Christ, G ^c   Gladwin, M T ^e,f   Hantgan, R R ^c   Kim Shapiro, D B ^b  

^a UNIVERSITY OF RICHMOND   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Hemoglobin; Hemolysis; Nitric oxide; Platelets; Red blood cells

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; APYRASE; DUAL SPECIFICITY PHOSPHATASE 2; HEMOGLOBIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FREE SYSTEM; DISEASE ASSOCIATION; ENZYME BINDING; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HEMATOLOGY EQUIPMENT; HEMOLYSATE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

HEMOGLOBIN; HEMOLYSIS; NITRIC OXIDE; PLATELETS; RED BLOOD CELLS;

ERYTHROCYTES; HEMOGLOBINS; HEMOLYSIS; HUMANS; NITRIC OXIDE; PLATELET ACTIVATION;

EID: 84889657091     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12422     Document Type: Article

References (46)

1. Ataga K. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009; 94: 1481-4.
2. Marcus EC. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 2001; 15: 44-54.
3. Gladwin MT, Kato GJ. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens! Haematologica 2008; 93: 1-3.
4. Karpman D, Manea M, Vaziri-Sani F, Stahl A, Kristoffersson A. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 128-45.
5. Wun T, Paglieroni T, Rangaswami A, Hill FP, Welborn J, Cheung A, Tablin F. Platelet activation in patients with sickle cell disease. Br J Haematol 1998; 100: 741-9.
6. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110: 2166-72.
7. Kenny M, George A, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 1980; 33: 622-5.
8. Iuliano L, Violi F, Pedersen JZ, Praticò D, Rotilio G, Balsano F. Free radical-mediated platelet activation by hemoglobin released from red blood cells. Arch Biochem Biophys 1992; 299: 220-4.
9. Born G, Bergquist D, Arfors K. Evidence for inhibition of platelet activation in blood by a drug effect on erythrocytes. Nature 1976; 259: 233-5.
10. Hu W, Jin R, Zhang J, You T, Peng Z, Ge X, Bronson RT, Halperin JA, Loscalzo J, Qin X. The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood 2010; 116: 1613-22.
11. Hellem A. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12(Suppl.): 1-117.
12. Gaarder A, Jonsen J, Laland S, Hellem A, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 11: 531-2.
13. Bergquist D, Arfors K. Haemostatic platelet plug formation in the isolated rabbit mesenteric preparation - an analysis of red blood cell participation. Thromb Haemost 1980; 44: 6-8.
14. Alkhamis TM, Beissinger RL, Chediak JR. Red blood cell effect on platelet adhesion and aggregation in low-stress shear flow: myth or fact? ASAIO J 1988; 34: 868-73.
15. Aursnes I, Stenberg-Nilsen H. Low dose infusion of adenosine diphosphate prolongs bleeding time in rats and rabbits. Thromb Res 1992; 68: 67-74.
16. Doni M, Aragno R. ADP-induced platelet aggregatioin in vivo after exclusion of different circulatory districts. Experientia 1975; 31: 1224-5.
17. Silvain J, Pena A, Cayla G, Brieger D, Bellemain-Appaix A, Chastre T, Vignalou J-B, Beygui F, Barthelemy O, Collet J-P, Montalescot G. Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the transfusion study. Eur Heart J 2010; 31: 2816-21.
18. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-8.
19. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75.
20. Bogle RG, Coade SB, Moncada S, Pearson JD, Mann GE. Bradykinin and ATP stimulate L-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 1991; 180: 926-32.
21. Silva G, Beierwaltes WH, Garvin JL. Extracellular ATP stimulates NO production in rat thick ascending limb. Hypertension 2006; 47: 563-7.
22. Ishida K, Matsumoto T, Taguchi K, Kamata K, Kobayashi T. Mechanisms underlying reduced P2Y1-receptor-mediated relaxation in superior mesenteric arteries from long-term streptozotocin-induced diabetic rats. Acta Physiol 2013; 207: 130-141.
23. Wollny T, Iacoviello L, Buczko W, DeGaetano G, Donati MB. Prolongation of bleeding time by acute hemolysis in rats: a role for nitric oxide. Am J Physiol Heart Circul Physiol 1997; 272: H2875-84.
24. Loscalzo J. Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis. Circ Res 2001; 88: 756-62.
25. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88: 411-15.
26. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon K. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819-22.
27. Huang KT, Huang Z, Kim-Shapiro DB. Nitric oxide red blood cell membrane permeability at high and low oxygen tension. Nitric Oxide Biol Chem 2007; 16: 209-16.
28. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, Olson JS, Lemon DD. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol 1998; 16: 672-6.
29. Herold S, Exner M, Nauser T. Kinetic and mechanistic studies of the NO-mediated oxidation of oxymyoglobin and oxyhemoglobin. Biochemistry US 2001; 40: 3385-95.
30. Butler AR, Megson IL, Wright PG. Diffusion of nitric oxide and scavenging by blood in the vasculature. BBA Gen Subjects 1998; 1425: 168-76.
31. Liu XP, Samouilov A, Lancaster JR, Zweier JL. Nitric oxide uptake by erythrocytes is primarily limited by extracellular diffusion not membrane resistance. J Biol Chem 2002; 277: 26194-9.
32. Azarov I, Huang KT, Basu S, Gladwin MT, Hogg N, Kim-Shapiro DB. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J Biol Chem 2005; 280: 39024-39032.
33. Azarov I, Liu C, Reynolds H, Tsekouras Z, Lee JS, Gladwin MT, Kim-Shapiro DB. Mechanisms of slower nitric oxide uptake by red blood cells and other hemoglobin-containing vesicles. J Biol Chem 2011; 286: 33567-79.
34. Vaughn MW, Huang KT, Kuo L, Liao JC. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem 2000; 275: 2342-8.
35. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscl Thromb Vasc 2006; 26: 697-705.
36. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003; 107: 271-8.
37. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 1383-9.
38. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107: 2279-85.
39. Reimers RC, Sutera SP, Joist JH. Potentiation by red-blood-cells of shear-induced platelet-aggregation - relative importance of chemical and physical-mechanisms. Blood 1984; 64: 1200-6.
40. Saniabadi AR, Lowe GDO, Forbes CD, Prentice CRM, Barbenel JC. Platelet-aggregation studies in whole human-blood. Thromb Res 1983; 30: 625-32.
41. Kehrel BE, Brodde MF. State of the art in platelet function testing. Transfus Med Hemother 2013; 40: 73-86.
42. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA 2005; 293: 1653-62.
43. Hamasaki N, Rose ZB. The binding of phosphorylated red blood cell metabolites to human hemoglobin A. J Biol Chem 1974; 249: 7896-901.
44. Morris CR, Kato GJ, Poijakovic M, Wang XD, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294: 81-90.
45. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood 2013; 121: 3733-41.
46. Pratico D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L, FitzGerald GA, Violi F. Iron-dependent human platelet activation and hydroxyl radical formation - involvement of protein kinase C. Circulation 1999; 99: 3118-24.